Cabanillas Beatriz
From the Department of Dermatology and Allergy, University Hospital Bonn, Germany; and Laboratory of Allergy, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
Dermatitis. 2023 Jan-Feb;34(1):21-28. doi: 10.1089/DERM.0000000000000905.
Dupilumab is a monoclonal antibody that represents the first approved targeted biological therapy for adults, adolescents, and children older than 6 years with moderate-to-severe atopic dermatitis (AD). Dupilumab binds the shared chain of the interleukin-4 and interleukin-13 receptor blocking the downstream signaling of these cytokines. The clinical improvements induced by dupilumab were associated with remission of the dysregulated immune mechanisms linked with AD. Dupilumab reversed the epidermal barrier defects and improved the global molecular signature of AD. This review seeks to provide an overview on the development of dupilumab as the first target-specific biological treatment for AD, with a description of the clinical trials that have been performed in different age groups, their outcomes, and reported adverse effects. Novel aspects of dupilumab treatment, as well as the current knowledge on the molecular and cellular mechanisms underlying the treatment of AD with dupilumab, are summarized and discussed.
度普利尤单抗是一种单克隆抗体，是首个获批用于治疗6岁及以上成人、青少年和儿童中重度特应性皮炎（AD）的靶向生物疗法。度普利尤单抗结合白细胞介素-4和白细胞介素-13受体的共享链，阻断这些细胞因子的下游信号传导。度普利尤单抗诱导的临床改善与AD相关的免疫机制失调缓解有关。度普利尤单抗逆转了表皮屏障缺陷，改善了AD的整体分子特征。本综述旨在概述度普利尤单抗作为AD首个靶点特异性生物治疗药物的研发情况，描述在不同年龄组进行的临床试验、试验结果及报告的不良反应。总结并讨论了度普利尤单抗治疗的新特点，以及目前关于度普利尤单抗治疗AD的分子和细胞机制的认识。
